tldrdailynews.com logo

Genesis Therapeutics Secures $200M Series B Funding for AI Drug Discovery and Clinical Testing

1 min read
Source: Endpoints News
Genesis Therapeutics Secures $200M Series B Funding for AI Drug Discovery and Clinical Testing
Photo: Endpoints News
TL;DR

Genesis Therapeutics has raised $200 million in Series B financing, co-led by Andreessen Horowitz and an anonymous life science investor. The startup, which utilizes artificial intelligence to design small molecule drugs, plans to use the funds to further develop its AI technologies, expand its pipeline, and advance its first computer-generated drugs into clinical studies.

Topics:businessbiotechnology#ai-drug-discovery#andreessen-horowitz#biotechnology#clinical-studies#genesis-therapeutics#series-b-financing
Share this article
  1. Genesis Therapeutics raises $200M for AI drug discovery based on Stanford research  Endpoints News
  2. Genesis Therapeutics Closes Oversubscribed $200 Million Series B  Business Wire
  3. Genesis Therapeutics Closes $200M Series B Funding  FinSMEs
  4. AI drug designer Genesis Therapeutics forges $200M round with eye on clinical testing  FierceBiotech
  5. View Full Coverage on Google News

Want the full story? Read the original reporting

Read on Endpoints News